BioMarin to Acquire Amicus Therapeutics for .8 Billion, Expanding Rare Disease Treatment Portfolio.

California-based biotech firm BioMarin Pharmaceutical Inc. has announced its intention to acquire Amicus Therapeutics, a rare disease company based in Princeton, New Jersey, in a cash transaction valued at .8 billion. This acquisition, expected to finalize in the second quarter of 2024, will expand BioMarin’s portfolio of treatments for rare genetic disorders, enhancing its operations in a competitive biotech landscape.

The acquisition positions BioMarin to benefit from Amicus’s offerings that generated approximately 9 million in revenue over the past year. With a strong existing infrastructure, BioMarin aims to integrate these assets to further boost its capabilities in addressing rare disease treatments. This transaction underscores BioMarin’s commitment to expanding its presence and impact in the biopharmaceutical market, especially in the realm of genetic disorders.

Amicus Therapeutics, known for its innovative approaches, has developed treatments for conditions such as Fabry disease, a genetic disorder that leads to the accumulation of fatty substances in the body, causing damage to various organs and tissues. Another key treatment under Amicus’s umbrella targets late-onset Pompe disease, which results in progressive muscle weakness. BioMarin’s Chief Executive Officer, Alexander Hardy, highlighted the significant revenue potential for these treatments, noting that they could each reach billion in global sales.

Despite Amicus’s promising product line, it reported lower revenues compared to BioMarin, which garnered .85 billion last year. The consolidation of these resources is anticipated to create synergies that may lead to enhanced financial performance for the combined entities.

Amicus has established a notable presence in the Philadelphia area, having opened its Global Research and Gene Therapy Center of Excellence in 2019 at 3675 Market St. This facility was initially projected to employ around 200 people, although current staffing has decreased to 12 after significant layoffs in research and development last year.

The Philadelphia region has become a focal point for biotech advancements, aided by notable institutions like the University of Pennsylvania, which has pioneered gene therapy research. The strategic relationship with these academic institutions is instrumental in fostering innovation in the biotech sector.

As BioMarin prepares to finalize the acquisition, the broader implications for the biotech industry will be closely monitored, particularly in the context of expanding R&D capabilities and addressing the needs of patients with rare diseases. This acquisition not only signifies a pivotal moment for both companies but also reflects ongoing trends in the biotech space toward consolidation to enhance efficiency and therapeutic development capabilities.